stockportfolio.pro
Stocks / CYTK vs HSIC
CYTK vs HSIC
Cytokinetics, Incorporated and Henry Schein, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Cytokinetics, Incorporated (CYTK) | Henry Schein, Inc. (HSIC) | |
|---|---|---|
| Market cap | $9.1B | $9.1B |
| Revenue (latest FY) | $88.04M | $13.18B |
| Net income (latest FY) | $-784.96M | $398.00M |
| Revenue growth (5y CAGR) | 9.5% | 5.4% |
| Net margin | -891.6% | 3.0% |
| Return on equity | 119.0% | 12.3% |
| P/E ratio | — | 24.2 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CYTK — free Open HSIC — freeFrequently asked questions
Which is bigger, CYTK or HSIC?
Henry Schein, Inc. is larger by market capitalization — $9.1B versus $9.1B.
Which grows faster, CYTK or HSIC?
Over the last five fiscal years, Cytokinetics, Incorporated grew revenue faster — 9.5%/yr versus 5.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.